First Tracks Biotherapeutics (NASDAQ:TRAX) Given Consensus Rating of “Moderate Buy” by Analysts

First Tracks Biotherapeutics (NASDAQ:TRAX) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $63.00.

Several research firms have issued reports on TRAX. Wedbush upped their target price on shares of First Tracks Biotherapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Wells Fargo & Company increased their price objective on shares of First Tracks Biotherapeutics from $30.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Piper Sandler lifted their target price on shares of First Tracks Biotherapeutics from $54.00 to $95.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. UBS Group increased their price target on First Tracks Biotherapeutics from $45.00 to $65.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, HC Wainwright lifted their price objective on First Tracks Biotherapeutics from $44.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, August 13th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of TRAX. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in First Tracks Biotherapeutics in the 2nd quarter worth $232,000. Corient Private Wealth LP bought a new stake in First Tracks Biotherapeutics during the 2nd quarter worth approximately $610,000. Wellington Management Group LLP bought a new position in shares of First Tracks Biotherapeutics in the second quarter worth approximately $1,156,000. Finally, California State Teachers Retirement System purchased a new stake in shares of First Tracks Biotherapeutics in the second quarter worth $10,643,000.

First Tracks Biotherapeutics Stock Performance

NASDAQ:TRAX opened at $41.86 on Monday. The company’s 50-day moving average price is $35.72. The company has a market cap of $1.50 billion and a price-to-earnings ratio of -22.75. First Tracks Biotherapeutics has a fifty-two week low of $14.72 and a fifty-two week high of $49.91.

First Tracks Biotherapeutics (NASDAQ:TRAX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.21). Sell-side analysts anticipate that First Tracks Biotherapeutics will post -4.31 EPS for the current fiscal year.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.